Head Of Oncology Rwe Strategic Planning
Salve esta vaga e mantenha sua pesquisa organizada
Crie uma conta gratuita para salvar vagas, criar alertas e retornar a esta listagem a partir do seu painel.
Ao continuar, você concorda com nossos Termos & Política de Privacidade.
The Chief Medical Affairs Office's Evidence Generation (EvGen) Platform is responsible for establishing global scientific leadership and stature through the generation of integrated, end-to-end observational real-world evidence serving all therapeutic areas from proof of concept (POC) trials through LOE for priority pipeline candidates, pipeline supplementation through business development, and marketed inline products.
The Platform fully centralizes RWE, epidemiology, outcomes research, RW-relevant health informatics, and biostatistics talent from global, international developed market (IDM) and emerging markets (EM) into one team to drive efficiency through internalized work.
The Platform functions to:enhance Pfizer's ability to determine unmet medical needs;support differentiated product labels for Product Development programs including finding alternatives and accelerated licensure pathways for new indications through the use of Real World Data (RWD), Real World Insights (RWI) and Real World Evidence (RWE);inform clinical practice on appropriate prescription and use of Pfizer's products;in collaboration with Access & Value, strengthen the value evidence package for payers and access/policy decision-makers;support measurement of short
- and long-term impact of Pfizer's products to both patients and populations;support competitive differentiation.
RWE, other patient-centric evidence, and RWI will be generated by the Platform for all global, prioritized IDM and prioritized EM needs through a combinatorial approach of cutting edge retrospective data analyses, site-based evaluations (e.g., Phase IV observational effectiveness studies, burden of illness, transmission, pathogenesis, risk factors for illness, determinants of product effectiveness and other studies), application of novel methods and technologies, and supplementation of interventional trials where appropriate with RWE through hybrid trial designs and tokenization.
The opportunity: This role is for a unique leader who is able to direct and manage teams and lead through influence across a wide variety of business verticals across the lifecycle, understand highly technical WE/Epidemiology/Statistical/Advanced Methods opportunities and communicate them to diverse audiences who lack expertise, create business plans and proposals, exhibit a high social IQ, and has deep experience with demonstrated history of success with global regulatory authorities, HTAs, and other stakeholders.
It plays a critical role in the development of a comprehensive RWE strategy, tactical plans, and projects that meet research and business needs at the global, regional and local level for priority markets worldwide.
They are key members of multiple layers of lifecycle and franchise or asset governance.
They will also provide matrixed leadership and oversight of all projects executed by Oncology RWE Science & Epidemiology and Clinical Affairs & Operations teams, restructuring priorities as needed based on shifting priorities for R&D and the business.
To carry out this work, they will be responsible for maintaining relationships with Oncology leadership (CxO, SVP and VP) from research, biopharma business and business innovation.
Finally, they will be an internationally-renowned external face of Pfizer, representing the organization and team at global industry events, conferences and symposia.
The position will lead a rapidly growing team through DP3, operational plans and the Seagen Integration of 5 individual contributor Sr Director Oncology RWE Strategic Planning franchise leaders dedicated to supporting the development of an Integrated Evidence Plan beginning on or before POC through LOE, evolving that plan & incorporating into relevant governance documents, accelerating and strengthening access for patients in priority markets worldwide with Global & Country Access and Value colleagues, ensuring that work by execution arms (RWE Science & Epidemiology for retrospective studies and Clinical Affairs for site-based prospective studies) is consistent with strategy, and other duties.
They will also lead cross-functional teams to consider myriad scenarios to proactively create alternative solutions based on headwinds and tailwinds.
The Head serve as single point of contact for all RWE planning readiness, strategic planning & tactical priority needs, incorporation of ex-US country CMAO colleagues' feedback into strategies and tactics wherever applicable, ensuring that RWE Strategies equate to high ROI and actionable project plans, and identifies novel innovation & efficiency opportunities.
They will serve as or assign duties as the Platform representative on all applicable Oncology franchise and asset governance committees (Global Product Teams, SLAC, Medical Strategy Teams, Integrated Value and Access Teams, etc.) across the lifecycle.
They will be responsible for directing their team to co-create integrated evidence plans early in the product lifecycle